BPI-472372: a potent and orally bioavailable small molecule inhibitor of CD73 for cancer immunotherapy

被引：0
|
作者：
Han, Han
Yang, Xiaofeng
Zhao, Ying
Wang, Jin
Yang, Xiang
Ju, Xuepeng
Zhao, Jiayu
Zou, Zhengyao
Chen, Haibo
Liu, Xiaoyun
Guo, Jing
Yang, Cheng
Lan, Hong
Wu, Hao
Ding, Lieming
Wang, Jiabing
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
504
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Investigation of CD73 expression in response to immunotherapy in pan-cancer
    Wang, Y.
    Liu, M.
    Hu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S893 - S893
  • [42] AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer
    Eckard, Sterling C.
    Chen, Yu
    Piovesan, Dana
    Narasappa, Nell
    Park, Timothy W.
    Kalisiak, Jarek
    Newcomb, Eric T.
    Leleti, Manmohan R.
    Soni, Divyank
    Ginn, Elaine
    Chen, Jie
    DiRenzo, Dan
    Zhang, Kristen
    Jin, Lixia
    Young, Stephen W.
    Walters, Matthew J.
    Schindler, Ulrike
    Powers, Jay P.
    CANCER RESEARCH, 2019, 79 (13)
  • [43] A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death
    Ray, Arghya
    Du, Ting
    Wan, Xueping
    Song, Yan
    Pillai, Sindhu C.
    Musa, Md. Abu
    Fang, Teng
    Moore, Jared
    Blank, Brian
    Du, Xiaohui
    Chen, Xi
    Warne, Robert
    Sutimantanapi, Dena
    Lui, Fang
    Zavorotinskaya, Tatiana
    Colas, Christophe
    Friedman, Lori
    Junttila, Melissa R.
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [44] ATG-037, a highly potent small molecule CD73 inhibitor has superior activity of reversing immunosuppression in higher-AMP environments compared with anti-CD73 antibodies
    Bian, Gang
    Hua, Jiahui
    Tian, Linjie
    Lynch, Kevin
    Mei, Jay
    Shan, Bo
    Hou, Bing
    CANCER RESEARCH, 2022, 82 (12)
  • [45] BPI-23314: A novel orally bioavailable small molecular BET inhibitor with target protein degradation activity
    Guo, Jing
    Xu, Yan
    Yan, Dan
    Yu, Bo
    Yu, Weiwei
    Chen, Haibo
    Xu, Xiaofeng
    Liu, Xiangyong
    Lan, Hong
    Ding, Lieming
    Wang, Jiabing
    CANCER RESEARCH, 2020, 80 (16)
  • [46] CD39/CD73/A2AR pathway and cancer immunotherapy
    Xia, Chenglai
    Yin, Shuanghong
    To, Kenneth K. W.
    Fu, Liwu
    MOLECULAR CANCER, 2023, 22 (01)
  • [47] CD39/CD73/A2AR pathway and cancer immunotherapy
    Chenglai Xia
    Shuanghong Yin
    Kenneth K. W. To
    Liwu Fu
    Molecular Cancer, 22
  • [48] Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor
    Leviten, Dina
    Sierra, Teresa
    Dozier, Ashley
    Boyce, Richard
    Boyle, Bob
    Peterson, Scott
    Vo, Alex C.
    CANCER RESEARCH, 2017, 77
  • [49] A novel orally bioavailable small molecular ENPP1 inhibitor (OC-1) for cancer immunotherapy
    Chen, Jiyun
    Pujala, Brahmam
    Gupta, Ashu
    Ansaria, Amantullah
    Khana, Farha
    Lee, Elbert
    Chakravarty, Sarvajit
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] NVP-BEP800: an orally bioavailable small molecule Hsp90 inhibitor with potent in vivo antitumor activity
    Jensen, Michael
    Schoepfer, Joseph
    Massey, Andrew
    Brough, Paul
    Brueggen, Josef
    Schweitzer, Alain
    Pfaar, Ulrike
    Quadt, Corneiia
    Drysdale, Martin
    Chene, Patrick
    Garcia-Echeverria, Carlos
    CANCER RESEARCH, 2009, 69
12345